TMCnet News
Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid TumorsSAN FRANCISCO and TAIPEI, Taiwan, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing cancer immunotherapy based on its novel ACC™ (Antibody Cell-Conjugation) technology platform, today announced it has received clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to initiate a Phase 1 clinical study of its natural killer (NK) cell therapy and lead drug candidate ACE1702 in patients with HER2-expressing solid tumors. “The FDA’s clearance of our IND for ACE1702 is a major milestone for Acepodia that represents an important initial validation of our ACC™ platform, which can link any antibody, including those that have already proven effective in targeting tumors, to proprietary off-the-shelf natural killer cell line (oNK cells) without the need for genetic engineering,” said Sonny Hsiao, Ph.D., chief executive officer of Acepodia, and the inventor of ACC™ while at University of California, Berkeley. “This novel approach allows us to circumvent the complexity and the limitations associated with CAR-T and traditional NK based cell therapies. ACC™ significantly improves manufcturing costs and has the potential to generate a cost-effective cancer treatment that can deliver increased benefit to patients. We look forward to advancing ACE1702 into its first clinical trial.” About ACE1702 About Acepodia Investor Contact |